Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 5/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | RBP4 | P02753 | 5/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | VNN1 | O95497 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3071276 | 1.00 | SCD5 (0.32) | SCD5PROKR1KDM5ARBP4TRPV1 | |
| SCHEMBL3071272 | 1.00 | SCD5 (0.32) | SCD5PROKR1KDM5ARBP4TRPV1 | |
| SCHEMBL3071271 | 1.00 | SCD5 (0.32) | SCD5PROKR1KDM5ARBP4TRPV1 | |
| SCHEMBL13256202 | 1.00 | SCD5 (0.32) | SCD5PROKR1KDM5ARBP4TRPV1 | |
| SCHEMBL3074619 | 1.00 | SCD5 (0.32) | SCD5PROKR1KDM5ARBP4TRPV1 | |
| SCHEMBL3063519 | 0.89 | KDM5A (0.32) | PROKR1KDM5ATRPV1VNN1IRAK4 | |
| SCHEMBL3063280 | 0.89 | KDM5A (0.32) | PROKR1KDM5ATRPV1VNN1IRAK4 | |
| SCHEMBL3063288 | 0.89 | KDM5A (0.32) | PROKR1KDM5ATRPV1VNN1IRAK4 | |
| SCHEMBL3063282 | 0.89 | KDM5A (0.32) | PROKR1KDM5ATRPV1VNN1IRAK4 | |
| SCHEMBL13256100 | 0.89 | KDM5A (0.32) | PROKR1KDM5ATRPV1VNN1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | BASKARAN SUBRAMANIAN | 2010-10-28 | — | — | US | disclosed |
| WO-2010091411-A1 | PIPERIDINYL CYCLIC AMIDO ANTIVIRAL AGENTS | GLAXOSMITHKLINE LLC (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272680-A1 | Piperidinyl Cyclic Amido Antiviral Agents | ZC3HAV1, MAVS, EIF2AK2 | SCD5 3866/4885PROKR1 1792/4885KDM5A 4081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.